These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 26523360

  • 1. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
    Watanabe T, Seguchi O, Nishimura K, Fujita T, Murata Y, Yanase M, Sato T, Sunami H, Nakajima S, Hisamatsu E, Sato T, Kuroda K, Hieda M, Wada K, Hata H, Ishibashi-Ueda H, Miyamoto Y, Fukushima N, Kobayashi J, Nakatani T.
    Int J Cardiol; 2016 Jan 15; 203():307-14. PubMed ID: 26523360
    [Abstract] [Full Text] [Related]

  • 2. Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience.
    Chou NK, Jan CF, Chi NH, Lee CM, Wu IH, Huang SC, Chen YS, Yu HY, Tsao CI, Ko WJ, Chu SH, Wang SS.
    Transplant Proc; 2012 May 15; 44(4):897-9. PubMed ID: 22564578
    [Abstract] [Full Text] [Related]

  • 3. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 15; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.
    Circ Heart Fail; 2018 Sep 15; 11(9):e004050. PubMed ID: 30354362
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI, Kang DY, Kim MS, Lee SE, Ahn JM, Lee JY, Kim YH, Park DW, Jung SH, Kim JJ.
    Atherosclerosis; 2022 Sep 15; 357():1-8. PubMed ID: 35981436
    [Abstract] [Full Text] [Related]

  • 8. Plasma neutrophil gelatinase-associated lipocalin and worsening renal function during everolimus therapy after heart transplantation.
    Imamura T, Kinugawa K, Doi K, Hatano M, Fujino T, Kinoshita O, Nawata K, Noiri E, Kyo S, Ono M.
    Int Heart J; 2015 Sep 15; 56(1):73-9. PubMed ID: 25742944
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO, Müller S, Konstandin M, Celik S, Kristen A, Frankenstein L, Ehlermann P, Sack FU, Katus HA, Dengler TJ.
    Transplant Proc; 2010 Nov 15; 42(9):3694-9. PubMed ID: 21094840
    [Abstract] [Full Text] [Related]

  • 13. Rapidly progressive cardiac allograft vasculopathy in early onset regressed with everolimus treatment in an adult cardiac recipient.
    Ishida J, Kinugawa K, Shiga T, Imamura T, Hatano M, Maki H, Inaba T, Yao A, Hirata Y, Nishimura T, Kyo S, Ono M, Nagai R.
    Int Heart J; 2012 Nov 15; 53(6):388-90. PubMed ID: 23258141
    [Abstract] [Full Text] [Related]

  • 14. Everolimus-incorporated immunosuppressant strategy improves renal dysfunction while maintaining low rejection rates after heart transplantation in Japanese patients.
    Imamura T, Kinugawa K, Ono M, Kagami Y, Endo M, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Komuro I.
    Int Heart J; 2013 Nov 15; 54(4):222-7. PubMed ID: 23924935
    [Abstract] [Full Text] [Related]

  • 15. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J, Machida Y, Iwai T, Kuwabara N, Kabei K, Naganuma T, Kumada N, Kawashima H, Nakatani T.
    Clin Transplant; 2014 Jan 15; 28(1):80-7. PubMed ID: 24329776
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
    Groetzner J, Kaczmarek I, Landwehr P, Mueller M, Daebritz S, Lamm P, Meiser B, Reichart B.
    Eur J Cardiothorac Surg; 2004 Mar 15; 25(3):333-41. PubMed ID: 15019657
    [Abstract] [Full Text] [Related]

  • 18. Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient.
    Imamura T, Shiga T, Kinugawa K, Kato N, Endo M, Inaba T, Maki H, Hatano M, Yao A, Hirata Y, Nagai R.
    Int Heart J; 2012 Mar 15; 53(3):199-201. PubMed ID: 22790690
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.